Novo Nordisk Buybacks Top DKK 6.4 Billion as Deutsche Bank and J.P. Morgan Square Off
Published on 10/08/2026 at 06:10 | Editorial boerse-global.de
Shares of Novo Nordisk finished Wednesday's session at EUR 34.06, a gain of 2.8% that offered a measure of relief in an otherwise downbeat market. No company-specific catalyst was identified for the advance, leaving investors to debate whether the move marks the start of a recovery or simply a technical bounce within a broader downtrend. Since the turn of the year, the Danish drugmaker's stock has shed 23%.
The uptick lands in the middle of an active share repurchase campaign. Between 28 September and 2 October, Novo Nordisk bought back 1,225,000 of its own B-shares for roughly DKK 307.4 million. That brings the running total under the current program past DKK 6.44 billion, part of a DKK 11.2 billion tranche within an overall buyback framework of up to DKK 15 billion. Management's willingness to keep buying signals confidence in the company's earnings power — and provides a steady source of demand for the stock.
Two Banks, Two Very Different Views
Analyst opinion is splitting sharply. Deutsche Bank Research cut its price target to DKK 225 from DKK 245 on Wednesday, keeping a Sell rating on the shares. The bank's reasoning: its read of the presentations and comparative studies unveiled at the European diabetes and obesity conference EASD came out slightly negative for Novo Nordisk, with competitive pressure mounting and questions building around long-term growth rates.
J.P. Morgan struck a more constructive tone on Monday, maintaining a Neutral rating with a DKK 275 target. The US bank argued that stronger-than-expected demand for the oral version of Wegovy could meaningfully lift third-quarter results — and if that momentum materializes, an upgrade to the full-year guidance becomes a real possibility. Such a revision would go a long way toward easing the recent selling pressure and could bring investors back quickly.
Oral Wegovy Emerges as the Swing Factor
That single product has become the fulcrum on which the bull and bear cases now rest. Whether the tablet delivers the hoped-for growth dynamic in the coming months will shape how the stock is valued. If demand outpaces estimates, Novo Nordisk gains breathing room; if it falls short, the lofty growth assumptions underpinning the valuation start to wobble.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Fresh clinical evidence offers some support. In an analysis of 55 participants from the STEP UP trial — patients with obesity but without diabetes — 88.5% of those with elevated liver fat recorded a fat content below 5% after 72 weeks on Wegovy. Separately, data from the OCTANE study showed that patients switching from injectable GLP-1 therapies to the Wegovy pill lost an average of 4.1% of body weight after three months. Establishing these oral formats quickly in the market could open the door to new patient populations.
Pipeline efforts extend beyond the metabolic franchise. A licensing deal with Hengrui covering HRS-1596, signed more than a month ago, underpins the longer-term outlook — though the stock has slipped 27.9% since that agreement was struck.
Regulatory Snag Adds to the Noise
A separate source of uncertainty has emerged outside the metabolism portfolio. Novo Nordisk confirmed in early October that the FDA has extended its review of Denecimig, a treatment for hemophilia A, after remediation work was required at a manufacturing site. The agency raised no concerns about efficacy or safety, but no new decision timeline has been set.
The company continues to target a US launch in the first half of 2027 and says the delay leaves its 2026 financial guidance untouched. Even so, the episode serves as a reminder that regulatory requirements and production processes remain a latent risk for any planned market entry.
A Chart Level and a Date to Watch
For now, the fundamental earnings base offers downside protection as long as support near the recent low holds. The 52-week trough sits at EUR 30.25, and a loss of confidence in revenue momentum ahead of the quarterly report could put that level back in play. Investors' room to maneuver has narrowed to that single marker.
Hard numbers will settle the argument between J.P. Morgan's optimism and Deutsche Bank's caution. Novo Nordisk is due to publish figures for the first three quarters of 2026 on 4 November 2026. That release will show whether the company can back up its annual targets — or whether mounting margin pressure in the diabetes and obesity markets has already started to leave marks on the books. Until then, the mood is one of tactical caution.
Ad
Novo Nordisk Stock: New Analysis - 8 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
